Antag Therapeutics

📍 Copenhagen, Denmark🗓 Founded 2017👥 22 employees💰 Last funded Aug 2022
Biotechnology🌐 antagtherapeutics.com
Website LinkedIn
Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option that goes beyond weight loss to improve long-term health, without having to compromise on tolerability.
5
Total investors
3
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Denmark
4
United Kingdom
1
Investor activity2017–2022 · investors recorded per year
20172201912020120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Antag Therapeutics?
Antag Therapeutics has 5 investors on record on gritt.io, including 3 early-stage backers, 2 mid-stage.
When did Antag Therapeutics last raise funding?
The most recent investment in Antag Therapeutics recorded on gritt.io was in August 2022.
When was Antag Therapeutics founded?
Antag Therapeutics was founded in 2017.
What industry is Antag Therapeutics in?
Antag Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Antag Therapeutics based?
Antag Therapeutics is headquartered in Copenhagen, Denmark.